CHOSOURCE: a platform for COVID-19-related therapeutics and diagnostics
Horizon Discovery Group has announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The CHOSOURCE platform includes a gene-edited glutamine synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognised in the industry and by regulators as suitable for high-yield biomanufacturing. The platform is already offered as a royalty-free alternative for the production of complex proteins and is empowering organisations from early-stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production.
Horizon is already a key supplier for research relating to COVID-19, providing many tools and services to academia and industry to support efforts in addressing the pandemic. This offering extends Horizon’s COVID-19 support portfolio.
Jesús Zurdo (pictured), Global Head Bioprocessing, Horizon Discovery, said: “The current coronavirus crisis is highlighting existing shortcomings in the development of much-needed therapeutics. Horizon Discovery is fully committed to help innovators in their efforts to develop new solutions to tackle the COVID-19 pandemic. We are providing immediate access to our state-of-the-art bioproduction platform under very favourable terms to facilitate such efforts.”